PO.TB04.07 · 肿瘤生物学
巨噬细胞吞噬作用与胞葬作用:对肿瘤微环境中治疗性调控的启示
Macrophage phagocytosis and efferocytosis: Implications for therapeutic modulation in the tumor microenvironment
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
巨噬细胞在肿瘤微环境中发挥核心作用。根据其激活状态和局部信号,它们可发挥促肿瘤和抗肿瘤双重效应。肿瘤相关巨噬细胞(TAM)常表现出免疫抑制性、促肿瘤的表型,促进肿瘤生长、血管生成、转移和治疗耐药。由于其可塑性以及在实体瘤中的丰度,TAM 是有吸引力的治疗靶点:既可将其重编程为抗肿瘤状态,亦可清除其肿瘤支持功能。鉴于巨噬细胞的双重作用,理解其在癌症中的行为对于开发有效的免疫疗法至关重要。这需要可靠、生理相关的体外检测,以建模关键功能,如吞噬作用、胞葬作用、细胞因子分泌和肿瘤细胞相互作用。
巨噬细胞吞噬作用和胞葬作用检测评估受试化合物对人类 M0、M1 和 M2 巨噬细胞摄取活性的影响。从冷冻保存的 PBMC 中分离 CD14+ 单核细胞,使用 M-CSF 分化为 M0 巨噬细胞六天,然后极化为 M1(IFN-gamma + LPS)、M2(IL-4 + IL-13)或 TAM 样(IL-4 + IL-10 + TGF-beta)表型。极化后,以确定的浓度和时间点用受试化合物处理细胞,随后与 pHrodo™ 生物颗粒或凋亡的 pHrodo™ 标记肿瘤细胞(喜树碱处理的 Raji 细胞)孵育,分别评估吞噬作用或胞葬作用。通过使用 Cytation 5 读板仪在 12-24 小时内测量红色荧光进行定量。
我们的实验表明,M0、M2 和 TAM 样巨噬细胞具有强大的吞噬和胞葬能力,而 M1 巨噬细胞对颗粒或凋亡肿瘤细胞的摄取极少。时间分辨分析揭示了不同的摄取动力学。M0 和 M2 巨噬细胞在 2-4 小时内快速内化靶标。然而,M0 细胞随后活性下降,而 M2 巨噬细胞维持持续平台期长达 12 小时,总体摄取更高。使用 LPS 和 IFN-gamma 将 M2 巨噬细胞重新极化为 M1 表型显著降低其吞噬能力。用抗 CD47 抗体阻断“不要吃我”信号显著增强对 Raji 细胞的胞葬作用。我们预期细胞因子谱分析将揭示由模式识别受体介导的吞噬作用与对组织稳态至关重要的胞葬作用之间的机制差异。
这些发现提示巨噬细胞的表型强烈影响其吞噬和胞葬行为,其中 M2 细胞表现出最高能力。调控巨噬细胞极化或解除抑制性信号的策略可增强这些功能,并支持对其治疗潜力的进一步研究。
查看英文原文 English abstract
Macrophages play a central role in the tumor microenvironment. Depending on their activation state and local signals, they can exert both pro- and anti-tumorigenic effects. Tumor-associated macrophages (TAMs) often exhibit an immunosuppressive, pro-tumoral phenotype that promotes tumor growth, angiogenesis, metastasis, and therapy resistance. Due to their plasticity and abundance in solid tumors, TAMs are attractive therapeutic targets: either by reprogramming them toward an anti-tumoral state or depleting their tumor-supportive functions. Understanding macrophage behavior in cancer is critical for developing effective immunotherapies, given their dual roles. This requires reliable, physiologically relevant in vitro assays modeling key functions, such as phagocytosis, efferocytosis, cytokine secretion, and tumor cell interaction.
Macrophage phagocytosis and efferocytosis assays assess the impact of test compounds on the uptake activity of human M0, M1, and M2 macrophages. CD14+ monocytes are isolated from cryopreserved PBMCs and differentiated into M0 macrophages using M-CSF for six days, then polarized into M1 (IFN-gamma + LPS), M2 (IL-4 + IL-13) or TAM-like (IL-4 + IL-10 + TGF-beta) phenotypes. After polarization, cells are treated with test compounds at defined concentrations and time points, followed by incubation with either pHrodo™ bioparticles or apoptotic pHrodo™ labelled tumor cells (camptothecin-treated Raji cells) to assess phagocytosis or efferocytosis, respectively. Quantification is performed by measuring red fluorescence over 12 - 24 hours using a Cytation 5 reader.
Our experiments indicate that M0, M2 and TAM-like macrophages have a strong capacity for phagocytosis and efferocytosis, while M1 macrophages have minimal particle or apoptotic tumor cell uptake. Time-resolved analysis reveals distinct uptake kinetics. M0 and M2 macrophages rapidly internalize targets within 2-4 hours. However, M0 cells subsequently decline in activity, while M2 macrophages maintain a sustained plateau for up to 12 hours with an overall higher uptake. Repolarizing M2 macrophages to an M1 phenotype using LPS and IFN-gamma markedly reduces their phagocytic capacity. Blocking the "don't eat me" signal with an anti-CD47 antibody significantly enhances the efferocytosis of Raji cells. We anticipate that cytokine profiling will reveal mechanistic differences between phagocytosis mediated by pattern recognition receptors and efferocytosis, which is critical for tissue homeostasis.
These findings suggest that the phenotype of macrophages strongly influences their phagocytic and efferocytic behavior, with M2 cells exhibiting the highest capacity. Strategies that modulate macrophage polarization or relieve inhibitory signals could enhance these functions and support further investigation into their therapeutic potential.
利益披露 Disclosure
V. Bergo,
Reaction Biology Europe GmbH Employment.
C. N. Castro,
Reaction Biology Europe GmbH Employment.
A. Bandini, None.
T. Sahner,
Reaction Biology Europe GmbH Employment.
S. Huber,
Reaction Biology Europe GmbH Employment.
S. Moor,
Reaction Biology Europe GmbH Employment.
P. Metzger,
Reaction Biology Europe GmbH Employment.
C. Obodozie,
Reaction Biology Europe GmbH Employment.
H. Weber,
Reaction Biology Europe GmbH Employment.